Cancer immunotherapy has emerged as a transformative approach in oncology, harnessing the body’s immune system to combat malignant tumors. Unlike conventional treatments such as chemotherapy and radiation, which often fail to prevent metastasis and cause significant systemic toxicity, immunotherapies aim to stimulate durable, tumor-specific immune responses. A key challenge lies in overcoming tumor-induced immunosuppression, where cancer cells evade immune detection through mechanisms like checkpoint upregulation and T cell exhaustion. To address these limitations, biomaterial carriers—particularly those based on aliphatic polyesters—have gained prominence due to their ability to precisely deliver immunomodulatory agents directly to immune cells.
Among these materials, poly(lactic acid) (PLA) and its copolymer, poly(lactic-co-glycolic acid) (PLGA), stand out for their biocompatibility, biodegradability, and tunable degradation kinetics. These polymers have been extensively used in drug delivery systems for over five decades, with FDA approval for various medical applications including sutures, implants, and controlled-release formulations. Their versatility stems from the ability to be engineered into diverse structures—nanoparticles, microparticles, hydrogels, and scaffolds—each tailored for specific delivery routes and therapeutic goals. The degradation of PLA and PLGA yields lactic and glycolic acids, naturally metabolized by the body, minimizing long-term accumulation and toxicity.
One of the most promising applications of PLA-based materials is in the development of cancer vaccines. Dendritic cells (DCs), central orchestrators of adaptive immunity, can be targeted by antigen-loaded particles to initiate robust anti-tumor T cell responses. PLGA nanoparticles effectively encapsulate tumor-associated antigens (TAAs) and adjuvants, enabling co-delivery within the same endosomal compartment—a prerequisite for efficient cross-presentation via MHC class I molecules. This process activates CD8+ cytotoxic T lymphocytes (CTLs), critical for killing tumor cells. Studies show that particle size significantly influences immune outcomes: optimal sizes around 20–200 nm facilitate rapid lymphatic drainage and efficient uptake by DCs in lymph nodes, whereas larger particles (>500 nm) require active transport by DCs, delaying immune activation.
Moreover, surface engineering enhances targeting specificity. Conjugating antibodies against DC surface receptors such as CD40 or DEC-205 improves particle uptake and antigen presentation. Mannose receptor-targeted particles further enhance binding to APCs expressing mannose receptors, promoting lymph node localization. In addition, strategies like lipid-coated PLGA particles allow low-dose antigen conjugation while maintaining sustained release profiles, reducing antigen burden and improving immune memory formation. Self-healing PLGA microspheres, developed through mild temperature-triggered pore collapse, protect antigens during encapsulation and enable prolonged release over weeks, significantly enhancing vaccine efficacy with single administration.
Beyond traditional vaccines, PLGA particles are being explored as artificial antigen-presenting cells (aAPCs). These synthetic platforms mimic natural DCs by presenting antigen-MHC complexes, delivering costimulatory signals (e.g., anti-CD28), and releasing stimulatory cytokines like IL-2. Larger aAPCs (~300 nm) have demonstrated superior T cell activation compared to smaller ones, likely due to enhanced stability and reduced phagocytic clearance. Shape also plays a role: nanoellipsoids evade macrophage uptake more effectively than spherical particles, prolonging circulation and boosting in vivo performance.
In recent years, the integration of PLGA-based materials with other therapeutic modalities has shown synergistic potential. Combining cancer vaccines with immune checkpoint blockade (ICB)—such as anti-PD-1 or anti-CTLA-4—has proven effective in reversing T cell exhaustion and amplifying anti-tumor immunity. Encapsulating ICB antibodies in PLGA nanoparticles reduces systemic exposure and mitigates adverse effects. Dual-functional nanoparticles co-displaying anti-PD-1 and agonist antibodies (e.g., anti-OX40) promote simultaneous inhibition of suppressive pathways and stimulation of effector functions, leading to improved tumor control in preclinical models.
Additionally, PLGA scaffolds implanted subcutaneously serve as localized depots for sustained release of antigens, adjuvants, and chemokines like GM-CSF.IP3 receptor Antibody MedChemExpress These porous matrices recruit immature DCs, support their maturation, and facilitate migration to draining lymph nodes, resulting in potent CTL responses.CD215 Antibody supplier Clinical translation of such platforms, exemplified by the WDvax scaffold currently under phase I trials for melanoma, highlights their translational promise.PMID:35013696
Despite these advances, challenges remain. The acidic degradation products of PLGA may destabilize proteins and nucleic acids. Achieving precise, programmable release kinetics—especially sequential delivery of multiple agents—is still limited by current formulation constraints. Furthermore, scaling production of sub-50 nm particles remains difficult, hindering lymph node-resident DC targeting. Future directions must focus on intelligent material design, incorporating stimuli-responsive elements, immune-modulating ligands, and multimodal functionalities to bridge the gap between preclinical success and clinical impact.
Ultimately, PLA and PLGA-based biomaterials represent a powerful platform for next-generation cancer immunotherapy. By enabling spatiotemporal control over immune activation, they offer unprecedented opportunities to reprogram the tumor microenvironment, induce lasting immune memory, and improve patient survival across diverse malignancies.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com